OTS: Boston Scientific Corporation / OrbusNeich und Boston Scientific legen ...

    OrbusNeich und Boston Scientific legen Rechtsstreit bei    Fort Lauderdale, Florida/Natick, Massachusetts (ots) - Die OrbusNeich Medical Inc. und die Boston Scientific Corporation (NYSE: BSX) haben heute alle Stent bezogenen Rechtsstreitigkeiten beigelegt. Die Übereinkunft klärt die Angelegenheiten beider Parteien in Deutschland, den Niederlanden, Irland, dem Vereinigten Königreich und in den Vereinigten Staaten. Die Einigung, welche eine Einmalzahlung von Boston Scientific an OrbusNeich beinhaltet, regelt alle Stent bezogenen Kontroversen zwischen den Firmen und enthält keine zukünftigen finanziellen Verpflichtungen.

   About OrbusNeich

   OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, and the world's first pro-healing stent, the Genous[TM] Stent. Other products include stents and balloons marketed under the names of Azule[TM], R stent, Scoreflex[TM], Sapphire[TM], Sapphire II and Sapphire NC. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

   About Boston Scientific

   Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

   Cautionary Statement Regarding Forward-Looking Statements

   This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding regulatory approvals, clinical trials, product performance and impact, and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

   Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

OTS:              Boston Scientific Corporation newsroom:         http://www.presseportal.de/pm/34137 newsroom via RSS: http://www.presseportal.de/rss/pm_34137.rss2 ISIN:             US1011371077

Pressekontakt: Géraldine Varoqui Media Relations Europe Boston Scientific International +49 2102 489461 (office) varoquig@bsci.com

Michael Campbell 508-650-8023 (office) Investor Relations Boston Scientific Corporation investor_relations@bsci.com

OrbusNeich Medical: Jamie Moser / Bryan Darrow Joele Frank, Wilkinson Brimmer Katcher +1 212-355-4449